Summary Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant melanoma. Nevertheless, substantial variability of survival suggests that metastatic cutaneous malignant melanoma can be divided into several biological subgroups. Pretreatment serum levels of soluble adhesion molecules and various clinical parameters in cutaneous metastatic malignant melanoma were evaluated to determine their prognostic value. In this study pretreatment serum levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), soluble intercellular cell adhesion molecule 1 (sICAM-1), soluble endothelial leukocyte adhesion molecule 1 (sE-selectin) and multiple clinical factors were assessed in relation to overall survival of 97 consecutive patients with metastatic cutaneous malignant melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, both univariate and multivariate Cox proportional-hazards models were used. Elevated pretreatment serum levels of sVCAM-1 (P < 0.005) and of lactate dehydrogenase (P < 0.002) were rendered statistically independent and were significantly associated with unfavourable outcome. Patients were assigned to one of three risk categories (low, intermediate and high) according to a cumulative risk score defined as the function of the sum of these two variables. There were significant differences in overall survival (P < 0.0001) between low-(n = 53, 5-year survival probability of 23.3%), intermediate-(n = 29, 5-year survival probability of 9.9%) and high-risk (n = 15) patients. Elevated pretreatment serum levels of sVCAM-1 and of lactate dehydrogenase correlate with poor outcome in metastatic cutaneous malignant melanoma. These data support risk stratification for future therapeutic trials and identify factors that need to be validated in prospective studies and may potentially influence decision-making in palliative management of patients with disseminated cutaneous malignant melanoma.
O-er the past decade. malignant melanoma has been one of the most rapidly increasing malignancies in human (Glass and Hoover. 1989 ). In the United States, the number of patients with malignant melanoma nearly doubled between 1980 and 1990 (Grin-Jorgensen et al. 1992) . Melanoma frequently affects young adults and is refractory to current methods of therapy once disseminated. with a median survival of 6-9 months (Legha. 1989 : Koh. 1991 . Nevertheless. substantial variability of survival suggests that metastatic malignant melanoma can be divided into several biological subgroups. Current methods to identify the aggressive potential of metastatic malignant melanoma are limited.
The ability of tumour cells to adhere to and to detach from extracellular matrix and endothelial cells may be crucial in tumour invasion and metastasis and may dramatically alter the clinical outcome for patients with cancer (Albelda, 1993; Newman. 1993: Frenette and Wagner 1996) . Several univariate studies have demonstrated that elevated serum levels of soluble adhesion molecules correlate with disease progression in malignant melanoma and might serve as prognostic markers (Harming et al. 1991 : Altomonte et al. 1992 : Banks et al. 1993 . Vascular adhesion molecule 1 (VCAM-1. CD 106) is a member of the immunoglobulin superfamily. expressed primarily on vascular endothelial cells and serves as a counter-receptor for the integrin a4PI . A soluble isoform of VCAM-l maintains the ability to bind VLA-4 and may serve as a mediator in the metastatic process of melanoma cells (Rice and Belivacqua. 1989 : Mould et al. 1994 : Garofalo et al. 1995 . Intercellular adhesion molecule 1 (ICAM-1. CD54) is a cell-surface molecule expressed on a variety of cell types: a soluble form of ICAM-1 (sICAM-1) is elevated in inflammation, infection and in cancers. including malignant melanoma. E-selectin. previously known as endothelial leukocyte adhesion molecule 1 (CD62e). is particularly interesting. because it is found only on activated endothelial cells. in contrast to other adhesion molecules. which have a wider tissue distribution. Endothelial cells have been shown to release Eselectin (sE-selectin) following in vitro activation (Piggot et al. 1992 . Serum levels of sE-selectin are significantly higher in melanoma patients than in normal donors (Fortis et al. 1995) .
We evaluated the prognostic value of elevated serum levels of soluble adhesion molecules sVCAM-1. sICAM-1. sE-selectin and of multiple clinical parameters in relation to overall survival in 97 consecutive patients with metastatic malignant melanoma using univariate and multivariate Cox proportional-hazards models. The purpose of this study was to identify prognostic factors for survival that may allow appropriate stratification in the management of metastatic malignant melanoma both in and outside clinical trials. Normal donor sera were obtained from healthy control subjects (n = 10): mean serum values ± s.e.m. for sVCAM-l. sICAM-l and sE-selectin concentrations of the healthy control group were 509 ngn ml-' + 14 ng ml-'. 208 ng ml-' + 12 ng ml-'. and 54 ng ml + 7 ng ml-' respectively.
METHODS

Patients and collection of samples
Statistical analysis
The statistical end point in our analysis was overall survival from time of entry into the study. We calculated univariate hazard ratios with 95% confidence intervals. using the Cox proportionalhazards model (Cox. 1972) . The simultaneous prognostic effect of various factors was determined in a multivariate analysis using the Cox proportional-hazards model (forward selection of variables).
The probability of overall survival was plotted over time according to the method of Kaplan and Meier (Kaplan and Meier. 1958) . Differences between groups in overall survival were tested with Breslow statistics. Clinical parameters and soluble adhesion molecules were tested as dichotomized prognostic variables. For age. time since tumour progression. time since tumour diagnosis.
erythrocyte sedimentation rate (ESR). neutrophil count. haemoglobin. sICAM-1. sVCAM-1 and sE-selectin, Kaplan-Meier estimates were performed. defining the best cut-off value as the value that best discriminates between poor and good overall survival.
For lactate dehydrogenase (LDH) and C-reactive protein (CRP). Patients were assigned to one of three risk categories (low, intermediate or high) according to cumulative rsk, defined as the functon of the sum of two independent variables, i.e. elevated serum levels of sVCAM-1 (> 770 ng ml) and LDH (> 240 U et).
the institutional upper normal limits w-ere chosen as cut-off (< 240 U 1-' and < 8 mg 1-1 respectixely).
RESULTS
Univanate analysis of pretreatment variables and survival
We analysed the ability of various clinical factors and of levels of soluble adhesion molecules to predict clinical outcome. The mean penod of follow-up for the surviving patients was 21 months (range 1-67 months). The median survival of all 97 patients entering the study was 10 months.
We calculated univariate hazard ratios with the Cox proportional-hazards model (Table 2 ). In this analysis. LDH. ESR. the presence of visceral metastases. liver disease and the number of metastatic sites had significant prognostic value with regard to overall survival. Elevated serum levels of LDH (> 240 U 1-') were present in 39 patients and were strongly associated with an unfavourable outcome: median survival in these patients was 5 months as opposed to patients with normal serum LDH (n = 58). who had a median survival of 16 months (P < 0.0001. Figure 1) . A tendency towards higher serum levels of LDH was found in patients with liver metastases (P = 0.001. chi-square test). Liver metastases were an important prognostic factor when examined by single-factor analysis (P < 0.004) and by multivariate analysis (P < 0.04). The median survival for patients with liver metastases was 6 months. compared with 11 months for patients without liver metastases. In general. only visceral disease was of significant prognostic value in univariate analysis (P = 0.004). It is notable All adhesion molecules tested had significant prognostic value. Elevated serum levels of sVCAMI-l (> 770 ng ml-. n = 20) were associated with the highest likelihood of an unfavourable outcome. The median survival for these patients was very poor (5 months) as opposed to patients in whom no elevated sVCAM-1 levels were observed (median survival 12 months. n = 57. P < 0.0001. Figure 2) .
Similarly, patients with elevated serum levels of sICAM-1 (. 290 ng ml-. n = 56. median survival. 6 months) and patients with elevated serum levels of sE-selectin (2 60 ng ml-'. n = 32. median survival. 6 months) had a reduced overall survival when compared with patients without elevated sICAM-l and sE-selectin respectively (median survival 16 and 13 months respectively. P < 0.02).
Multivariate analysis of risk factors
To identify the most powerful prognostic factors. we established a multivariate Cox proportional-hazards model containing those factors with significant prognostic value upon univariate analysis. The following three factors were found to be significant: liver metastases (P < 0(04). serum LDH (P < 0.002) and sVCAM-l (P < 0.005). The hazard ratios calculated with a model containing these prgnostic factors are shown in Table 3 . Factors also evaluated and found not to be independent by multivariate analyses included evaluated ESR. visceral disease, more than one metastatic site. sICAM and sE-selectin. These results were the same even after accounting for palliative chemotherapy. This complex model resulted in numerous prognostic subgroups of small sizes and, therefore. it appeared inappropriate for further statistical verification.
Development of a cumulative risk model
On the basis of those two pretreatment prognostic parameters of highest statistical significance. which were rendered independent upon multivariate analysis. i.e. elevated serum levels of sVCAM-1 and LDH. patients were assigned to one of three nrsk categories: low risk. defined as the absence of either risk factor: intermediate risk. defined as the presence of one risk factor: and high risk. defined as the presence of both risk factors (Figure 3 ). There were significant differences in overall survival (P < 0.0001) between low-risk (n = 53, median survival 16 months. 5-year survival probability 23.3%). intermediate-risk (n = 29. median survival 6 months. 5-year survival probability 9.9%c) and high-risk patients (n = 15. median survival 5 months. 5-year survival probability BrSish Journal of Cancer (1998) 78(1) (5) more than one metastatic site and (6) elevated serum levels of soluble adhesion molecules VCAM-1. ICAM-1 and E-selectin. Multivariate analysis showed that elevated serum levels of sVCAM-I (P < 0.005) and of LDH (P < 0.002) were the dominant independent prognostic variables. When combining elevated sVCAM-1 and serum LDH we were able to identify a subgroup of patients at highest nrsk. all of whom died of disease within 1 year. In contrast. intermediate-risk patients exhibiting one of the two pretreatment risk factors reached a 5-year survival probability of 10%. whereas median survival was similar to high-risk patients. In comparison with high-and intermediate-risk patients, the subgroup at lowest risk demonstrated a median survival of 16 months and a 5-year survival probability of 23%. This risk stratification suggested that metastatic cutaneous malignant melanoma patients can be divided into several biological subgroups: however. the present model needs to be validated in prospective trials.
LDH has been reported as a prognostic parameter in metastatic malignant melanoma, in correlation with tumour burden (Heimdal et al. 1989 : Sirott et al. 1993 ). An elevated serum LDH does not necessarily indicate liver metastasis. In this study. 40% of patients had elevated serum levels of LDH. but only 26% had confirmed liver metastases. Moreover, serum LDH and the presence of liver metastases were independent prognostic markers upon multivariate analysis. The reduced survival of patients with more than one metastatic site confirms the findings of Balch et al (1983) .
However. in the present study the number of metastatic sites was not of independent significance. This may be explained in part by Figure 3 Kaplan-Meler curves of patient categones stratified according to cumulative risk of elevated pretreatment serum sVCAM-1 and LDH in 97 patients with metastatic cutaneous malignant melarnoa. The study population of patents wih metastatic cutaneous malignant melarnma was analysed according to elevated pretreatment serum levels of sVCAM-1 and LDH. Patients were assigned to one of three risk categories according to cumulative risk, defined as the functon of the sum of two independent varables, i.e. elevated serum levels of sVCAM-1 (> 770 ng ml-) and LDH (> 240 U h1). P-value was determined by og-rank test. lick marks represent patients for whom data were censored the inclusion of serum LDH in this study. which achieved statistical significance as a more accurate marker of tumour burden.
Erythrocyte sedimentation rate, which is a known unspecific marker in various human malignancies, did not reach statistical independence in the prognosis of metastatic malignant melanoma We were able to confirrm and extend earlier reports of elevated serum levels of sICAM-1 and sE-selectin in metastatic malignant melanoma patients. Although in this multivariate analysis. sEselectin and sICAM-1 were of no prognostic xalue. sVCAM-1 presented as an independent predictor of survival for patients with Conversely, down-regulation of VCAM-1 on endothelial cells has been identified as a potential mechanism of melanoma escape from cytotoxic lymphocyte surveillance (Piali et al. 1995) . Several other preclinical parameters have been reported as prognostic variables in metastatic malignant melanoma. Primary tumour-or metastasis-related parameters include cytogenetic abnormalities. DNA ploidy and S-phase fraction, the expression of metastasis associated gene products. the S100 protein and the detection of circulating melanoma cells in peripheral blood using reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosinase messenger RNA (Trent et al. 1990 ; Smith et al. 1991; Xerri et al. 1994 : Karlson et al. 1996 : Kunter et al. 1996 : Buer et al. 1997 . Although all of these malignant melanoma-associated features reflect isolated aspects of tumour biology, in the present study we were able to define a new and highly specific parameter potentially indicative of tumour cell-extracellular matrix interaction and its impact on survival in malignant melanoma.
In conclusion. elevated pretreatment serum levels of sVCAM-1 and of LDH correlate with poor outcome in cutaneous metastatic malignant melanoma. These data support risk stratification for future therapeutic trials. and identify factors that may potentially influence decision-making in palliative management of patients with disseminated malignant melanoma. In addition. an improved understanding of the endothelial matrix-associated mechanisms of tumour cell adhesion and invasion may provide a lead for future therapeutic strategies focusing on the regulation of endothelial function and damage in human malignancies. Our results will have to be confirmed prospectively in future controlled studies.
